
    
      This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose
      study. Twenty-four subjects with Rheumatoid Arthritis will be selected to participate.
      Subjects will be randomized to receive either ABT-122 or placebo. ABT-122 or placebo will be
      administered as subcutaneous (under the skin) injections in three dosing groups.
    
  